AirSculpt Technologies (NASDAQ:AIRS) Major Shareholder Jorey Chernett Purchases 105,848 Shares

AirSculpt Technologies, Inc. (NASDAQ:AIRS) major shareholder Jorey Chernett bought 105,848 shares of AirSculpt Technologies stock in a transaction dated Monday, March 16th. The stock was acquired at an average price of $2.43 per share, for a total transaction of $257,210.64. Following the completion of the acquisition, the insider owned 6,592,059 shares in the company, valued at approximately $16,018,703.37. The trade was a 1.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Wednesday, March 11th, Jorey Chernett purchased 88,000 shares of AirSculpt Technologies stock. The stock was acquired at an average cost of $2.15 per share, with a total value of $189,200.00.
• On Friday, March 6th, Jorey Chernett purchased 45,600 shares of AirSculpt Technologies stock. The stock was bought at an average price of $2.00 per share, with a total value of $91,200.00.
• On Wednesday, March 4th, Jorey Chernett acquired 30,000 shares of AirSculpt Technologies stock. The shares were bought at an average cost of $1.87 per share, for a total transaction of $56,100.00.
• On Tuesday, March 3rd, Jorey Chernett acquired 80,000 shares of AirSculpt Technologies stock. The shares were bought at an average price of $1.71 per share, for a total transaction of $136,800.00.

AirSculpt Technologies Price Performance

NASDAQ:AIRS traded up $0.96 during midday trading on Monday, hitting $2.81. 76,986,341 shares of the company traded hands, compared to its average volume of 711,116. The firm’s fifty day moving average is $2.23 and its 200-day moving average is $4.66. AirSculpt Technologies, Inc. has a 12-month low of $1.51 and a 12-month high of $12.00. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.51 and a current ratio of 0.51.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AirSculpt Technologies in a research note on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $6.00.

Hedge Funds Weigh In On AirSculpt Technologies

Several hedge funds have recently bought and sold shares of AIRS. Virtu Financial LLC bought a new position in shares of AirSculpt Technologies in the fourth quarter worth about $30,000. Millennium Management LLC bought a new stake in AirSculpt Technologies during the 4th quarter valued at about $33,000. Aigen Investment Management LP purchased a new stake in AirSculpt Technologies in the 4th quarter valued at about $36,000. Wells Fargo & Company MN boosted its position in AirSculpt Technologies by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 19,275 shares of the company’s stock valued at $38,000 after buying an additional 6,420 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in AirSculpt Technologies by 239.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,952 shares of the company’s stock worth $48,000 after acquiring an additional 4,199 shares in the last quarter. Institutional investors own 91.54% of the company’s stock.

About AirSculpt Technologies

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.